Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: A cohort study in the Philippines

PLoS Medicine

Volumn 3, Issue 9, 2006, Pages 1587-1596

  Tupasi, Thelma E ^a   Gupta, Rajesh ^b,c   Quelapio, Ma Imelda D ^a   Orillaza, Ruth B ^a   Mira, Nona Rachel ^a   Mangubat, Nellie V ^a   Belen, Virgil ^a   Arnisto, Nida ^a   Macalintal, Lualhati ^a   Arabit, Michael ^a   Lagahid, Jaime Y ^d   Espinal, Marcos ^b   Floyd, Katherine ^b  

^a Tropical Disease Foundation   (Philippines)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF HEALTH   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CREATININE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; STREPTOMYCIN; URIC ACID; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ARTHRALGIA; ARTICLE; BARTER SYNDROME; BLURRED VISION; BRONCHOSPASM; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEATH; DEPRESSION; DIARRHEA; DISABILITY; DIZZINESS; DRUG COST; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SENSITIVITY; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; GOUT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEARING LOSS; HEART PALPITATION; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; PERIPHERAL NEUROPATHY; PHILIPPINES; PHOTOPHOBIA; PILOT STUDY; PSYCHOSIS; SIDE EFFECT; TASTE DISORDER; TINNITUS; TREATMENT FAILURE; TUBERCULOSIS; URIC ACID BLOOD LEVEL; VERTIGO; WEAKNESS; AGED; COMPARATIVE STUDY; DIRECTLY OBSERVED THERAPY; ECONOMICS; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIRECTLY OBSERVED THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHILIPPINES; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 33749013310     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030352     Document Type: Article

References (45)

1. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, et al. (2001) Global trends in resistance to antituberculosis drugs. New Engl J Med 344: 1294-1303.
2. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, et al. (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization - International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. New Engl J Med 338: 1641-1649.
3. World Health Organization, IUATLD (2004) Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance Report No. 3. Geneva: WHO.
4. World Health Organization (2006) Global tuberculosis control: Surveillance, planning, financing. WHO/HTM/TB/2006.362. WHO: Geneva.
5. Espinal M, Kim SJ, Suarez P, Kam KM, Khomenko AG, et al. (2003) Standard short-course chemotherapy for drug resistant tuberculosis. Treatment outcomes in six countries. JAMA 283: 2537-2545.
6. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, et al. (2002) Frequency of recurrence among MDR-TB cases "successfully" treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 6: 858-864.
7. Mukherjee JS, Rich RM, Socci AR, et al. (2004) Programmes and principles in treatment of multi-drug resistant tuberculosis. Lancet 363: 474-481.
8. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: A national cohort study in Peru. Lancet 359: 1980-1989.
9. Tahaoglu K, Torun T, Sevim T, Atac G, Kir A , et al. (2001) The treatment of multidrug-resistant tuberculosis in Turkey. New Engl J Med 345: 170-174.
10. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, et al. (2004) Self-administered, standardized regimens for multi-drug resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 8: 361-368.
11. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New Engl J Med 348: 119-128.
12. Palmero DJ, Ambroggi M, Brea A, De Lucas M, Fulgenzi A, et al. (2004) Treatment and follow-up of HIV-negative multidrug resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 8: 778-784.
13. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, et al. (2005) Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study. Lancet 365: 318-326.
14. Geerligs WA, van Altina R, Lange WCM, van Soolingen D, van der Werf TS (2000) Multi-drug resistant tuberculosis: Long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 4: 758-764.
15. Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, et al. (1995) Multidrug-resistant tuberculosis in patients without HIV infection. New Engl J Med 333: 907-911.
16. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, et al. (2001) Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 120: 343-348.
17. Viskum K, Kok-Jensen A (1997) Multidrug-resistant tuberculosis in Denmark 1993-1995. Int J Tuberc Lung Dis 1: 299-301.
18. Avendano M, Goldstein RS (2000) Multidrug-resistant tuberculosis: Long-term follow-up of 40 non-HIV infected patients. Can Respir J 7: 383-389.
19. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, et al. (2004) Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 169: 1103-1109.
20. Flament-Saillour M, Robert J, Jarlier V, Grosset J (1999) Outcome of multidrug-resistant tuberculosis in France. A nationwide case-control study. Am J Respir Crit Care Med 160: 587-593.
21. Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, et al. (2001) Responding to market failures in tuberculosis control. Science 293: 1048-1051.
22. World Health Organization (2002) An expanded DOTS framework for effective tuberculosis control. WHO/CDS/TB/2002.297. Geneva: WHO.
23. World Health Organization (2000) Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). WHO/CDS/TB/2000.279. Geneva: WHO.
24. Gupta R, Cigielski JP, Espinal MA, Henkens M, Kim JY, et al. (2002) Increasing transparency in partnerships for health - Introducing the Green Light Committee. Trop Med Int Health 7: 970-976.
25. Tupasi TE, Quelapio MID, Orillaza RB, Alcantara C, Mira NR, et al. (2003) DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: Global assistance urgently needed. Tuberculosis 82: 52-58.
26. World Bank (2006) Phillipines data profile. Available: http://devdata. worldbank.org/external/CPProfile.asp?PTYPE=CP&CCODE=PHL. Accessed 29 July 2006.
27. Rivera AB, Tupasi TE, Balagtas ED, Cardano RC, Baello BQ, et al. (1999) Drug-resistant tuberculosis in the Philippines. Int J Tuberc Lung Dis 3: 639.
28. World Health Organization (1997) Treatment of tuberculosis: Guidelines for national programmes. 2nd edition. WHO/TB/97.220. Geneva: WHO.
29. Quelapio MID, Mira NRC, Abeleda MR (2000) Directly observed therapy-short course (DOTS) at the Makati Medical Center. Phil J Microbiol Inf Dis 29: 80-86.
30. Laserson KF, Thorpe LE, Leimaine V, Weyer K, Mitnick CD, et al. (2005) Speaking the same language: Treatment outcomes for multidrug resistant tuberculosis. Int J Tuberc Lung Dis 9: 640-645.
31. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes. 2nd edition. Oxford: Oxford University Press. 379 p.
32. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press. 456 p.
33. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC (1996) The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 276: 1172-1177.
34. Lew W (1996) The fate of intractable multi-drug resistant tuberculosis cases under national tuberculosis programme in Korea. London: London School of Hygiene and Tropical Medicine.
35. Quy HT, Giang DC, Lan NTN, Borgdorff MW, Quy NC, et al. (2004) Follow-up of chronic tuberculosis patients in Ho Chi Minh City, Vietnam. The Hague: KNCV (Royal Dutch Tuberculosis Association).
36. World Health Organization (2005). The feasibility and efficiency of controlling MDR-TB using the DOTS-Plus strategy in the Russian Federation. WHO/HTM/TB/2005.357c. Geneva: WHO.
37. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, et al. (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New Engl J Med 328: 527-532.
38. Murray CJL, Lopez ADeditors (1996) The Global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press. 1022 p.
39. Murray CJL, Ahmad OB, Lopez AD, Salomon JA (2001) WHO system of model life tables: GPE discussion paper series No. 8. Geneva: World Health Organization. EIP/GPE/EBD.
40. Pathania VS, Trnka L, Krejbich F, Dye C (1999) A cost-benefit analysis of BCG revaccination in the Czech Republic. Vaccine 17: 1926-1935.
41. Styblo K (1991) Epidemiology of tuberculosis. 2nd edition. The Hague: Royal Netherlands Tuberculosis Association (KNCV).
42. de Jonghe E, Murray CJ, Chum HJ, Nyangulu DS, Salomao A, et al. (1994) Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania. Int J Health Plann Manage 9: 151-181.
43. Vynnycky E, Fine PEM (1998) The long-term dynamics of tuberculosis and other diseases with long serial intervals: Implications of and for changing reproduction numbers. Epidemiol Infect 121: 309-324.
44. World Bank (1993) World development report: Investing in health. New York: Oxford University Press.
45. World Health Organization (2002) World health report 2002: Reducing risks, promoting healthy life. Geneva: WHO.